OBJECTIVES: To investigate the effect of pharmacist’s intervention on the cost of clinical pathway for gastric cancer operation.

METHODS: Patients with gastric cancer who completed the clinical pathway in our hospital were selected as research objects.95 patients (before the intervention) collected during Sep.-Nov. 2017 were the control group and 89 patients (after the intervention) collected during Dec. 2017-Feb.2018 were the study group. The rationality and incidence of adverse reactions were compared between the two groups of patients with antibiotics, nutritional support drugs, analgesic drugs, and acid-suppressing drugs. The length of hospital stay, postoperative hospital stay, hospitalization cost, and drug cost were compared between the two groups.

RESULTS: Compared with the control group, the treatment duration and cost of the antibacterial drugs used in the study group, the medication time and the incidence of adverse reactions of the nutritional drugs, and the medication time of the acid-suppressing drugs were significantly lower than the control group, with statistical significance (p< 0.05); The per capita hospitalization costs and per capita drug costs in the study group were reduced by 2160.69 RMB and 1127.34 RMB compared with the control group, the difference was statistically significant (p<0.05), but there was no statistical difference in the length of hospital stay and postoperative hospital stay between the two groups (p<0.05).

CONCLUSIONS: Pharmacist’s intervention can significantly reduce the cost of clinical pathways for gastric cancer operation and effectively improve the quality of clinical pathway management.